Red blood cell distribution width to platelet ratio: A prognostic biomarker in glioblastoma?


  • Overall survival (OS) was significantly improved in patients with a pre-surgical red blood cell distribution width (RDW)-to-platelet ratio (RPR) <0.05. RPR is captured in routine laboratory values and a feasible personalized prognostic biomarker in glioblastoma (GBM).

Why this matters

  • The prognosis of newly-diagnosed GBM remains poor despite significant activity in the field. Tools to match patients to the most appropriate management strategies based on expected clinical benefit are essential.

  • RDW and RPR are routinely captured in pre-surgical GBM laboratory bloodwork and are known prognostic indicators in several diseases. Unlike traditional inflammatory markers such as C-reactive protein or white blood cell count, these measures may be more precise and more robust to transient medications (e.g., glucocorticoids) and conditions (e.g., acute infection).

  • It is possible that pre-operative RPR could be associated with survival outcomes in patients with GBM.